Latham Advises on US$50 Million Investment in Lotus Pharmaceutical

A corporate deal team advised Thailand’s largest listed conglomerate in the transaction.

May 31, 2021

Lotus Pharmaceutical Co., Ltd., an Alvogen company, has announced the issuance of new shares through private placement to be acquired by Innobic (Asia), a wholly owned subsidiary of PTT Public Company Limited (PTT). Latham & Watkins advised PTT in the transaction.

Under the agreement, Innobic (Asia), PTT's Pharmaceutical and Life Science arm, commits to an investment of approximately US$50 million, to subscribe 17,517,348 new shares via private placement at the price of NT$80.7 per share. This strategic investment aims to further strengthen market access in the ASEAN region, including but not limited to Thailand, Vietnam, Philippines, and Malaysia.

PTT is the largest publicly listed conglomerate in Thailand and the nation's only company listed in the Fortune Global 500. Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets.

The deal team was led by Hong Kong partner Posit Laohaphan and Singapore partner Marcus Lee with associate Jirasin Watanatornpitak.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.